Study of HN2302 for hard-to-treat myasthenia gravis
Part of Brain & nervous system, Cancer, Immune system & allergy clinical trials.
This trial tests a new medicine called HN2302 for people with generalized myasthenia gravis (MG) that hasn't improved with standard treatments. It aims to see if HN2302 is safe and helps reduce muscle weakness symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old
- You have generalized myasthenia gravis (not just eye symptoms) and have antibodies called AchR or MuSK
- Your MG symptoms are moderate to severe, with an ADL score of 6 or higher
- Your current treatments haven't worked well enough or have become ineffective
- You don't have serious infections, a history of organ transplantation, or severe heart or brain conditions
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment made from donor immune cells (CAR-NK cells) that are designed to target and destroy the B cells causing your muscle weakness. It is for people with refractory myasthenia gravis who have not improved enough with standard therapies.
This trial tests a new drug called HN2301 for patients with generalized myasthenia gravis (a disease where the immune system weakens muscles) who have not responded well to standard treatments. The goal is to see if HN2301 can safely improve muscle strength and daily function.
This early trial tests a new injection called GC012F in people with generalized myasthenia gravis that hasn't improved with standard treatments. The goal is to see if it can help reduce muscle weakness and improve daily life.
This study tests a new drug called SHR-2173 to help people with generalized myasthenia gravis (a condition where muscles weaken because the immune system blocks communication between nerves and muscles). The drug is designed to work with treatments you're already taking to improve muscle strength and reduce symptoms.
This study tests an investigational drug called GC012F for people with generalized myasthenia gravis (gMG) that hasn't improved with standard treatments. The goal is to see if it can reduce symptoms and improve daily life.
This trial tests a new immune cell treatment (CAR T-cells) for people with generalized myasthenia gravis that has not improved with standard treatments. It aims to reduce symptoms by targeting and calming the immune system's attack on muscles.
Hear when a new Refractory Myasthenia Gravis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.